End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1.69 USD | +5.62% | +19.52% | -51.44% |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 3.46M 3.8M 303M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 10 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.11% |
Latest transcript on Altamira Therapeutics Ltd.
1 day | +5.62% | ||
1 week | +19.52% | ||
Current month | -18.36% | ||
1 month | -18.36% | ||
3 months | -15.50% | ||
6 months | -49.58% | ||
Current year | -51.44% |
Managers | Title | Age | Since |
---|---|---|---|
Thomas Meyer
CEO | Chief Executive Officer | 56 | 31/03/03 |
Marcel Gremaud
DFI | Director of Finance/CFO | 66 | 31/10/21 |
Covadonga Pañeda
COO | Chief Operating Officer | 51 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Alain Munoz
BRD | Director/Board Member | 75 | 28/02/18 |
Mats Blom
BRD | Director/Board Member | 59 | 31/03/17 |
Thomas Meyer
CEO | Chief Executive Officer | 56 | 31/03/03 |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 1.69 | +5.62% | 166,284 |
25/04/24 | 1.6 | +11.11% | 322,810 |
24/04/24 | 1.44 | -8.86% | 3,000,617 |
23/04/24 | 1.58 | +12.86% | 110,808 |
22/04/24 | 1.4 | -0.99% | 107,242 |
End-of-day quote Nasdaq, April 25, 2024
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-51.44% | 3.79M | |
-2.62% | 103B | |
+1.78% | 95.28B | |
+1.46% | 22.15B | |
-15.66% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.14% | 16.05B | |
+4.54% | 13.68B | |
+35.31% | 12.17B |
- Stock Market
- Equities
- CYTO Stock